These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 35987605)

  • 1. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Sinopharm's BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave.
    Belayachi J; Mhayi A; Majidi H; El Fahime E; Abouqal R
    Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
    Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
    Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
    PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
    Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
    Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
    Nadeem I; Ul Munamm SA; Ur Rasool M; Fatimah M; Abu Bakar M; Rana ZK; Khatana UF; Jordon L; Saqlain M; Mahdi N; McLoughlin H
    Postgrad Med J; 2023 Jun; 99(1171):463-469. PubMed ID: 37294716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021.
    Katz MA; Rojas Castro MY; Chakhunashvili G; Chitadze N; Ward CL; McKnight CJ; Lucaccioni H; Finci I; Zardiashvili T; Pebody R; Kissling E; Sanodze L
    PLoS One; 2024; 19(9):e0307805. PubMed ID: 39240827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
    Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
    JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
    Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M
    BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China.
    Zeng T; Wang K; Guo Z; Sun S; Zhai Z; Lu Y; Teng Z; He D; Wang K; Tian M; Zhao S
    Infect Dis Ther; 2023 Oct; 12(10):2405-2416. PubMed ID: 37768483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
    Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.